{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": "CDC_Influenza_vaccines",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": false,
    "additional_count": 0
  },
  "completeness_stats": {
    "existing_evidence": 1,
    "new_evidence_found": 0,
    "total_evidence": 1
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "RIV4 (recombinant HA vaccine)",
      "relevance_explanation": "This quote identifies RIV4 as a recombinant hemagglutinin (HA) vaccine, which is relevant because recombinant technology is the basis for the claim about broader immune response and potential cross-protection. However, the document does not provide explicit statements about the breadth of immune response or cross-protection, so this is the only directly relevant segment."
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}